## **Core Concept**
Thromboembolism associated with oral contraceptive pills (OCPs) is primarily related to the **estrogen** component. Estrogen can increase the synthesis of clotting factors in the liver, leading to a hypercoagulable state.

## **Why the Correct Answer is Right**
The correct answer, **estrogen**, is implicated in increasing the risk of thromboembolism because it enhances the production of clotting factors such as fibrinogen, prothrombin, and factors VII, VIII, IX, and X. This results in a prothrombotic state, which can lead to the formation of blood clots. The risk is particularly increased in women who are over 35 years old, smoke, or have other risk factors for cardiovascular disease.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Progesterone-only pills have a lower risk of thromboembolism compared to combined estrogen-progesterone pills. While progesterone can have some effects on coagulation, it is not the primary component associated with thromboembolism.
- **Option B:** This option is not specified, but if referring to a specific type of progesterone, it's essential to note that the risk associated with thromboembolism is more directly linked to estrogen.
- **Option D:** This option is also not specified, but given the context, it's clear that estrogen is the component most directly associated with an increased risk of thromboembolism.

## **Clinical Pearl / High-Yield Fact**
A crucial point to remember is that the risk of thromboembolism is higher with **combined oral contraceptives** (those containing both estrogen and progesterone) than with **progesterone-only pills**. Women with a history of thromboembolic events or those at high risk should be carefully evaluated before being prescribed OCPs.

## **Correct Answer:** . estrogen